Announcements Trials
Browse Landscape

Phase

Phase 2 2

Status

Unknown 2Not yet recruiting 2Recruiting 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 22Gastrointestinal 8Head & Neck 5Sarcoma 3Gynecologic 3Breast 3Tumor-Agnostic 2Genitourinary 2Endocrine 1Dermatologic 1CNS 1

Conditions

Carcinoma, Renal Cell 2

Interventions

Gemcitabine 13Radiotherapy 12Androgen Antagonists 12Specimen Handling 11Magnetic Resonance Spectroscopy 10pembrolizumab 9Nivolumab 8toripalimab 7darolutamide 7Drug Therapy 7Radiosurgery 6Docetaxel 6Cystectomy 6enzalutamide 5apalutamide 5Mitomycin 5Cisplatin 5Axitinib 5Abiraterone Acetate 5disitamab vedotin 4cabozantinib 4abiraterone 4Pluvicto 4Cyclophosphamide 4tislelizumab 3lenvatinib 3fludarabine 3cemiplimab 3Sunitinib 3Standard of Care 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Not yet recruiting × anlotinib × Genitourinary × Clear all
NCT07602101 2026-05-22

Neoadjuvant PD-L1 Inhibitor Plus Anlotinib for Kidney Preservation in Complex Renal Cell Carcinoma

RenJi Hospital

Phase 2 Not yet recruiting
33 enrolled
Genitourinary

Carcinoma, Renal Cell

NCT07470840 2026-03-24

SBRT Plus Anlotinib and Bimepolizumab in Locally Advanced or Metastatic Renal Cell Carcinoma

Fujian Cancer Hospital

Phase 2 Not yet recruiting
27 enrolled
Genitourinary

Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡